The verdict
Our read at a glance.
Whether aprotinin is understood as a withdrawn-in-the-US antifibrinolytic peptide that reduced surgical bleeding but raised the risk of death and kidney injury versus cheaper alternatives, rather than a drug still in routine use.
- The signal
- Aprotinin reliably reduced blood loss and transfusion in major cardiac surgery, which is why it was widely used. But observational studies and the randomized BART trial found higher rates of death and kidney injury compared with the cheaper lysine-analog antifibrinolytics, leading to its worldwide suspension in 2007 and 2008. Later re-analysis led the EU and Canada to reinstate it with restrictions for isolated cardiac surgery, while it remains off the US market.
- The unknown
- Whether, used narrowly in carefully selected cardiac-surgery patients, aprotinin's bleeding benefit can be had without the excess mortality seen earlier, the question behind its restricted reinstatement abroad, remains debated, and it has largely been replaced by tranexamic acid.
- Our read
- A cautionary classic. Aprotinin, a protease-inhibitor protein from cow pancreas, genuinely reduced bleeding in heart surgery but was pulled worldwide after a randomized trial linked it to more deaths and kidney injury than cheaper alternatives. Read it as a withdrawn drug, reinstated only with restrictions in some countries, and a sharp reminder that reducing bleeding, the thing that was measured, is not the same as saving lives, the thing that mattered.
The mechanism
How it works.
Blood clotting is balanced by enzymes that build clots and enzymes (proteases) that break them down. Aprotinin is a small protein from cow pancreas that blocks several of those proteases at once, most importantly plasmin, the enzyme that dissolves clots, and kallikrein, which drives part of the inflammation and clot-breakdown set off by the heart-lung bypass machine. By damping those, aprotinin keeps clots stable and reduces bleeding during major surgery. The problem was never whether it reduced bleeding, which it did; it was that, compared with cheaper drugs that block clot breakdown a different way (the lysine analogs like tranexamic acid), patients given aprotinin died and developed kidney failure more often, which is what ended its routine use.
Safety & regulatory boundary
The consequential part.
Aprotinin can cause severe allergic reactions, including anaphylaxis, especially on repeat exposure, since it is a cow-derived protein, and it was linked to higher rates of death and kidney failure than cheaper antifibrinolytics, which is why it was withdrawn worldwide in 2007 and 2008. It is not marketed in the US. The EU and Canada later reinstated it with restrictions for isolated coronary bypass surgery, but tranexamic acid is generally preferred. It is a surgical drug given in the operating room, never a wellness or consumer peptide.
What's next
What we're watching.
Whether restricted, carefully-monitored use abroad shows an acceptable safety profile, ongoing comparisons with tranexamic acid, and any change in its US regulatory status.
Context
Why this is discussed.
Aprotinin is a cautionary classic: a protein from cow pancreas that genuinely cut bleeding in heart surgery, was used for years, and was then pulled from the market when a randomized trial found more deaths than with cheaper alternatives. Its messy story, withdrawal and then partial reinstatement abroad, is a lesson in how a drug can help on the thing you measure (bleeding) while hurting on the thing that matters most (survival).
The evidence base
8 cited references.
Indexed literature (PubMed)8
Deanda A Jr et al. · J Thorac Cardiovasc Surg · 2012
DeAnda A Jr · J Thorac Cardiovasc Surg · 2008
Dhir A · Ann Card Anaesth · 2013
Beverly A et al. · Cochrane Database Syst Rev · 2023
Aggarwal NK et al. · Ann Card Anaesth · 2020
Wong BI et al. · Ann Thorac Surg · 2000
Henry D et al. · CMAJ · 2009
Schertz K et al. · Pediatr Crit Care Med · 2022
Keep reading